Alicia Ciccone

The US FDA has approved safinamide as adjunctive therapy in Parkinson’s disease to increase “on” time

Patients with inherited thrombophilias who did not undergo patent foramen ovale closure faced a significantly increased risk of stroke.

Marathon sells off its controversial DMD drug as the FDA stands to double its fees for the drug approval process under the new Trump budget.

For the second time, the US FDA is warning physicians and patients to be aware of an experimental procedure that is being promoted as a treatment in autonomic dysfunction.

The Obamacare replacement is here, and opposition is growing among medical groups. Plus, alternative medicine is having its moment at some major hospitals, while telemedicine proves to be a bust for health care costs.

While Genentech rolls the dice on a second phase 3 trial for its anti-amyloid agent, a new biotech startup is tapping CRISPR technology to restore dystrophin production in Duchenne muscular dystrophy.

Optimal antiplatelet treatment has yet to be determined for stroke survivors with prior intracerebral hemorrhage.

Follow timely coverage of the International Stroke Conference right here on Neurology Advisor.

Delays related to the determination of treatment eligibility increased door-to-needle times by more than 30 minutes compared with patients with no delays.

Neither lying flat nor sitting up appears to alter outcomes in patients presenting with acute stroke.

Among ICH survivors, 63% developed both depression and dementia during a 5-year follow-up study.

Just days after it received FDA approval, Marathon’s Emflaza is under fire from critics who claim the price of the Duchenne muscular dystrophy drug is exorbitant.

Patients who participated in a group course with other people with epilepsy felt less isolated and more confident.

Still feeling aftershocks from its failed Alzheimer’s trial, Eli Lilly announced more layoffs while Biogen faces an investigation into its payment programs for its top MS drugs.

Five years after treatment, nearly 70% of patients with relapsing-remitting multiple sclerosis showed no signs of disease progression.

Traumatic brain injury continues to make major headlines as a new crop of lawsuits hit the docket ahead of Super Bowl LI. Plus, are we too quick to rush to in-human trials? The authors of an op-ed in Nature think so.

Despite being more common than thought, many cases of neonatal hemorrhagic stroke remain idiopathic.

The USPSTF concluded that there is insufficient evidence to assess the reported risks and benefits of OSA screening in asymptomatic adults.

One US town tries to take Big Pharma to court over the opioid crisis while the FDA continues to approve new, abuse-deterrent opioids. Plus, the first patient with refractory mesial temporal lobe epilepsy has undergone laser ablation surgery as part of the SLATE trial.

Researchers report 2 cases of a severe B-cell-mediated CNS disease after treatment with alemtuzumab in patients with multiple sclerosis.

UCB Pharma looks to expand its epilepsy drug as Biogen cuts a deal to protect Tecfidera, while insiders suggest that pharmacists should play a bigger role in managing the growing Alzheimer’s dementia population.

A significant inverse trend was observed between the Healthy Nordic Food Index and risk of stroke.

The medical community questions whether mobile stroke units are sustainable, new research further links concussions with Alzheimer’s disease, and a new trial examines the effects of fasting on MS.

Women who were pregnant and slept for less than 6 hours per night or had poor sleep quality had a greater risk of developing gestational diabetes.

The US FDA has approved the first drug for the treatment of spinal muscular atrophy, a genetic disease that often results in premature death.

Nearly 60% of patients had achieved seizure freedom at last follow-up, 10 to 21 years after surgery.

Happy New Year! Reflect on some of 2016’s greatest neurological advances and look forward as institutions like the NIH take on a focused effort to explore new drugs for rare disease, the developing brain, and more.

Patients who received ACE inhibitors showed a slower progression of myocardial fibrosis and fewer cardiovascular events.

The US FDA is requiring that label changes be made to reflect the risks involved with extended exposure to anesthetics and sedatives in children and pregnant women.

The NCAA honored the man and ALS patient behind the viral ALS Ice Bucket Challenge, while the UK approved mitochondrial replacement reproductive assistance and Bristol-Myers Squibb faces a $20 million fine for promoting off-label uses of its antipsychotic Abilify.